Identification and prioritization of gene sets associated with schizophrenia risk by co-expression network analysis in human brain

• Published in: Molecular psychiatry 2020-04, Vol.25 (4), p.791-804
• Main Authors: Radulescu, Eugenia, Jaffe, Andrew E., Straub, Richard E., Chen, Qiang, Shin, Joo Heon, Hyde, Thomas M., Kleinman, Joel E, Weinberger, Daniel R.
• Format: Article
• Language: English
• Subjects: 38; 38/23; 38/39; 38/91; 631/208; 692/699/476/1799; Adult; Aged; Aged, 80 and over; Analysis; Autopsy; Behavioral Sciences; Biological Psychology; Brain; Brain - metabolism; Diagnosis; Drug development; European Continental Ancestry Group - genetics; Female; Gene expression; Gene Regulatory Networks - genetics; Genes; Genetic aspects; Genetic Predisposition to Disease - genetics; Genetic susceptibility; Genome-Wide Association Study - methods; Genomics - methods; Health aspects; Humans; Identification and classification; Male; Medicine; Medicine & Public Health; Mental disorders; Middle Aged; Multifactorial Inheritance - genetics; Neurogenetics; Neuroplasticity; Neurosciences; Pharmacotherapy; Prefrontal Cortex - metabolism; Psychiatric research; Psychiatry; Ribonucleic acid; Risk factors; RNA; Schizophrenia; Schizophrenia - genetics; Synaptic plasticity; Therapeutic targets; Transcription; Transcriptome - genetics
• ISSN: 1359-4184; 1476-5578
• DOI: 10.1038/s41380-018-0304-1

Schizophrenia polygenic risk is plausibly manifested by complex transcriptional dysregulation in the brain, involving networks of co-expressed and functionally related genes. The main purpose of this study was to identify and prioritize co-expressed gene sets in a hierarchical manner, based on the strength of the relationships with clinical diagnosis and with polygenic risk for schizophrenia. Weighted Gene Co-expression Network Analysis (WGCNA) was applied to RNA-quality-adjusted DLPFC RNA-Seq data from the LIBD Postmortem Human Brain Repository (90 controls, 74 schizophrenia cases; all Caucasians) to construct co-expression networks and detect “modules” of co-expressed genes. After multiple internal and external validation procedures, modules of selected interest were tested for enrichment in biological ontologies, for association with schizophrenia polygenic risk scores (PRSs) and with diagnosis, and also for enrichment in genes within the significant GWAS loci reported by the Psychiatric Genomic Consortium (PGC2). The association between schizophrenia genetic signals and modules of co-expression converged on one module showing not only a significant association with both diagnosis and PRS but also significant overlap with 36 PGC2 loci genes, deemed the strongest candidates for drug targets. This module contained many genes involved in synaptic signaling and neuroplasticity. Fifty-three PGC2 genes were in modules associated only with diagnosis and 59 in modules unrelated to diagnosis or PRS. Our study highlights complex relationships between gene co-expression networks in the brain and clinical state and polygenic risk for SCZ and provides a strategy for using this information in selecting and prioritizing potentially targetable gene sets for therapeutic drug development.